Bengaluru-based at-home diagnostics company Inito on Thursday announced that it has raised $29 million in its Series B funding round led by Bertelsmann India Investments and co-led by existing investor Fireside Ventures.
The latest fundraise brings Inito’s total equity funding to $45 million, per a company statement.
Inito launched its first fertility monitor in 2021 with the goal to make quantitative hormone diagnostics possible at home. The company claims to have analysed more than 30 million hormone data points.
Inito’s flagship fertility monitor captures a continuous dataset of hormone biomarkers at scale, enabling users to measure FSH, Estrogen, LH, and PdG (urine metabolite of Progesterone). From there, Inito’s AI models interpret these measurements to reveal hormone patterns that help users understand their bodies.
Inito said it is moving beyond fertility to build a broader at-home hormone and health diagnostics platform powered by AI-engineered antibodies.
“We have always believed that healthcare should start at home. Hormones shape fertility, mood, metabolism, sleep, and energy, yet reliable testing still relies on clinic infrastructure,” said Aayush Rai and Varun AV, co-founders of Inito.
“If you want to understand your hormones, you shouldn’t have to wait weeks for a lab report, you should be able to do it from home, with clinical-grade technology. AI-engineered antibodies allow us to build diagnostic tests that simply were not possible before.”
Inito boasts 20+ patents, a database of over 30 million fertility hormone tests, and a growing global team across Dubai, Bangalore, and London.
